Literature DB >> 19956490

Usefulness of additional delayed regional F-18 Fluorodeoxy-Glucose Positron Emission Tomography in the lymph node staging of Non-Small Cell Lung Cancer patients.

Young So1, June-Key Chung, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee.   

Abstract

PURPOSE: In this study, we examined whether additional, delayed regional FDG PET scans could increase the accuracy of the lymph node staging of NSCLC patients.
MATERIALS AND METHODS: Among 87 patients who underwent open thoracotomy or mediastinoscopic biopsy under the suspicion of NSCLC, 35 (32 NSCLC and 3 infectious diseases) who had visible lymph nodes on both preoperative whole body scan and regional FDG PET scan were included. The following 3 calculations were made for each biopsy-proven, visible lymph node: maximum SUV of whole body scan (WB SUV), maximum SUV of delayed chest regional scan (Reg SUV), and the percent change of SUV between WB and regional scans (% SUV Change). ROC curve analyses were performed for WB SUVs, Reg SUVs and % SUV Changes.
RESULTS: Seventy lymph nodes (29 benign, 41 malignant) were visible on both preoperative whole body scan and regional scan. The means of WB SUVs, Reg SUVs and % SUV Changes of the 41 malignant nodes, 3.71+/-1.08, 5.18+/-1.60, and 42.59+/-33.41%, respectively, were all significantly higher than those of the 29 benign nodes, 2.45+/-0.73, 3.00+/-0.89, and 22.71+/-20.17%, respectively. ROC curve analysis gave sensitivity and specificity values of 80.5% and 82.8% at a cutoff of 2.89 (AUC 0.839) for WB SUVs, 87.8% and 82.8% at a cutoff of 3.61 (AUC 0.891) for Reg SUVs, and 87.8% and 41.4% at a cutoff of 12.3% (AUC 0.671) for % SUV Changes.
CONCLUSION: Additional, delayed regional FDG PET scans may improve the accuracy of lymph node staging of whole body FDG PET scan by providing additional criteria of Reg SUV and % SUV Change.

Entities:  

Keywords:  FDG PET; Lymph node staging; Non-small cell lung cancer; Standardized uptake value

Year:  2005        PMID: 19956490      PMCID: PMC2785397          DOI: 10.4143/crt.2005.37.2.114

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  18 in total

1.  Regional lymph node classification for lung cancer staging.

Authors:  C F Mountain; C M Dresler
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

2.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck.

Authors:  R Hustinx; R J Smith; F Benard; D I Rosenthal; M Machtay; L A Farber; A Alavi
Journal:  Eur J Nucl Med       Date:  1999-10

3.  FDG-PET in oncology: there's more to it than looking at pictures.

Authors:  A J Fischman; N M Alpert
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

4.  Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer.

Authors:  A R Boerner; M Weckesser; H Herzog; T Schmitz; W Audretsch; U Nitz; H G Bender; H W Mueller-Gaertner
Journal:  Eur J Nucl Med       Date:  1999-03

5.  Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake.

Authors:  R Kubota; K Kubota; S Yamada; M Tada; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1994-01       Impact factor: 10.057

6.  Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.

Authors:  C K Hoh; R A Hawkins; J A Glaspy; M Dahlbom; N Y Tse; E J Hoffman; C Schiepers; Y Choi; S Rege; E Nitzsche
Journal:  J Comput Assist Tomogr       Date:  1993 Jul-Aug       Impact factor: 1.826

7.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?

Authors:  L M Hamberg; G J Hunter; N M Alpert; N C Choi; J W Babich; A J Fischman
Journal:  J Nucl Med       Date:  1994-08       Impact factor: 10.057

8.  Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose.

Authors:  M Reivich; A Alavi; A Wolf; J Fowler; J Russell; C Arnett; R R MacGregor; C Y Shiue; H Atkins; A Anand
Journal:  J Cereb Blood Flow Metab       Date:  1985-06       Impact factor: 6.200

9.  Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.

Authors:  V J Lowe; D M DeLong; J M Hoffman; R E Coleman
Journal:  J Nucl Med       Date:  1995-05       Impact factor: 10.057

10.  High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue.

Authors:  S Yamada; K Kubota; R Kubota; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

View more
  5 in total

Review 1.  Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.

Authors:  Thomas C Kwee; Sandip Basu; Drew A Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

Review 2.  KSNM60 in Clinical Nuclear Oncology.

Authors:  Seung Hwan Moon; Young Seok Cho; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-08-31

3.  Imaging Atherosclerosis in the Carotid Arteries with F-18-Fluoro-2-deoxy-D-glucose Positron Emission Tomography: Effect of Imaging Time after Injection on Quantitative Measurement.

Authors:  Minyoung Oh; Ji Young Kim; Kwang-Ho Shin; Seol Hoon Park; Jin-Sook Ryu; Jae Seung Kim; Hye-Jin Kim; Dong-Wha Kang; Dae Hyuk Moon
Journal:  Nucl Med Mol Imaging       Date:  2010-08-27

4.  Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy.

Authors:  Hyun-Cheol Kang; Hong-Gyun Wu; Tosol Yu; Hak Jae Kim; Jin Chul Paeng
Journal:  Radiat Oncol J       Date:  2013-09-30

5.  18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.

Authors:  Stephen P Povoski; Douglas A Murrey; Sabrina M Smith; Edward W Martin; Nathan C Hall
Journal:  BMC Cancer       Date:  2014-06-19       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.